Literature DB >> 18293890

Time-dependent effects on coronary remodeling and epicardial conductance after intracoronary injection of enriched hematopoietic bone marrow stem cells in patients with previous myocardial infarction.

Marc Vanderheyden1, Steven Vercauteren, Samer Mansour, Leen Delrue, Bart Vandekerckhove, Guy R Heyndrickx, Inge Van Haute, Bernard De Bruyne, Frank Timmermans, William Wijns, Jozef Bartunek.   

Abstract

Bone marrow (BM) cells may interact with coronary endothelium and modulate coronary atherosclerosis. We investigated the time course of coronary luminal loss and changes in conductance after intracoronary injection of enriched hematopoietic BM stem cells in patients with previous myocardial infarction (MI). Among 24 patients with acute MI, 13 were randomized to early (<7 days) and 11 to late (4 months) intracoronary injection of CD133+ cells after the infarction. Segmental quantitative coronary angiography and fractional flow reserve (FFR) measurements of the infarct-related (IR) artery (A) and contralateral artery (control) were performed. In the early group, at 4 months, cumulative luminal loss (LL) of the minimal luminal diameter (MLD) of the IRA distal to the stented segment was -0.39 (-0.51-0.10) mm (p < 0.05 vs. control). There was no further change in LL between 4 and 8 months [-0.09 (-0.26-0.15) mm]. In parallel, FFR decreased at 4 months [-0.16 (-0.26-0.001), p < 0.05 vs. control] but slightly increased from 4 to 8 months follow-up [+0.05 (-0.10-0.09)]. In the late group, LL of the MLD of the IRA distal to the stented segments was -0.12 (-0.47-0.07) mm (NS vs. control) at 4 months and further -0.07 (-0.25-0.05) mm (NS) between 4 and 8 months. At 8 months, the total LL of the MLD in the early and late group was only slightly higher compared to control [-0.34 (-0.48--0.16), -0.36 (-0.69--0.09), and -0.12 (-0.39-0.05) mm, respectively, NS]. Early intracoronary administration of hematopoietic BM stem cells in patients with previous MI is associated with accelerated luminal loss and reduced conductance of the infarct-related artery.

Entities:  

Mesh:

Year:  2007        PMID: 18293890     DOI: 10.3727/096368907783338244

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  8 in total

Review 1.  Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges.

Authors:  Jörn Tongers; Douglas W Losordo; Ulf Landmesser
Journal:  Eur Heart J       Date:  2011-02-28       Impact factor: 29.983

Review 2.  Endothelial progenitor cells in cardiovascular disease and chronic inflammation: from biomarker to therapeutic agent.

Authors:  Johannes C Grisar; Francois Haddad; Fatemeh A Gomari; Joseph C Wu
Journal:  Biomark Med       Date:  2011-12       Impact factor: 2.851

Review 3.  Cell therapy for cardiovascular disease: a comparison of methods of delivery.

Authors:  Nabil Dib; Harris Khawaja; Samantha Varner; Megan McCarthy; Ann Campbell
Journal:  J Cardiovasc Transl Res       Date:  2010-12-23       Impact factor: 4.132

4.  One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction.

Authors:  Samer Mansour; Denis-Claude Roy; Vincent Bouchard; Louis Mathieu Stevens; Francois Gobeil; Alain Rivard; Guy Leclerc; François Reeves; Nicolas Noiseux
Journal:  Bone Marrow Res       Date:  2011-02-27

5.  Immuno-modification of enhancing stem cells targeting for myocardial repair.

Authors:  Jiashing Yu; Yuan-Kun Wu; Yiping Gu; Qizhi Fang; Richard Sievers; Chun-Hua Ding; Jeffrey E Olgin; Randall J Lee
Journal:  J Cell Mol Med       Date:  2015-04-23       Impact factor: 5.310

Review 6.  Critical Roles of Reactive Oxygen Species in Age-Related Impairment in Ischemia-Induced Neovascularization by Regulating Stem and Progenitor Cell Function.

Authors:  Yuen Ting Lam
Journal:  Oxid Med Cell Longev       Date:  2015-11-30       Impact factor: 6.543

Review 7.  Endothelial progenitor cells in cardiovascular diseases: from biomarker to therapeutic agent.

Authors:  Hui-Bin Liu; Yuan-Feng Gong; Chang-Jiang Yu; Ying-Ying Sun; Xin-Yuan Li; Dan Zhao; Zhi-Ren Zhang
Journal:  Regen Med Res       Date:  2013-12-06

Review 8.  Targeted Therapy in Cardiovascular Disease: A Precision Therapy Era.

Authors:  Mengda Xu; Jiangping Song
Journal:  Front Pharmacol       Date:  2021-04-16       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.